Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio.
Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes :
Each theme is rated taking into account several comprehensive sub-categories.
Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter. Indeed, our process is supported by a network of local experts that have a deep knowledge of each local market best practices (from both customs and regulatory points of views).
If you are interested in the Proxinvest Corporate Governance Rating ®, please contact directly Proxinvest ( or +33(0)1 45 51 50 43).
Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
GENMAB - BUY | DKK1600 vs. DKK1550 (+1%) ASH19: R&D day shed the light on DuoBody CD3xCD20 Promising data from Genmab’s own bi-spec CD3xCD20 Preclinical candidates are on track SC Darzalex should get approval in Q2 next year
Overweight Global Technology & Industrials The absence of breakdowns in both the US dollar (DXY) and the MSCI EAFE vs. EM ratio along with the positive correlation between the two allows us to continue sticking with EAFE over EM... see charts below. As long as the DXY's uptrend remains intact, we expect EAFE to continue outperforming EM. Below we highlight attractive and actionable themes within developed int'l markets: • Technology and Industrial Manufacturing. Technology and Industrials continue to be two of the most attractive Sectors globally -- overweight. These two Sectors account fo...
MANQUE DE TRANSPARENCE : Encore une fois, nous alertons les actionnaires concernant le manque de transparence de la société Bastide le Confort Médical vis-à-vis de son rapport financier ; tant au niveau des conventions réglementées, tant concernant la politique de rémunération.Par ailleurs, dans le cadre de l’exercice du mandat Monsieur Guy Bastide, ce dernier est assisté par Messieurs Vincent Bastide, Arnaud Fayolle, Olivier Jourdanney, Benoit Quencez et Pierre-Marie Varachaud en qualité de Directeurs Généraux Adjoints. Proxinvest regrette que les rémunérations de Vincent Bastide, Olivier Jou...
The group operates a dual listed company structure. Standard UK shareholder rights apply to Investec plc shareholders. Investec Ltd is incorporated and listed in South Africa. A Special Voting Share enables the shareholders of Investec plc to vote on the resolutions proposed at meetings of Investec Ltd. Investec proposes to approve a demerger of its Asset Management business, called “Ninety One Businessp”Under the UK legal requirements and due to the groupns duallisted company structure (DLC), the approval will be sought at a general meeting of Investec plc and a general meeting of Investec L...
La nomination de David Horn Solomon au sein du Conseil d'administration s'effectue dans la perspective de le nommer Président du Conseil d'administration. Ce nouveau mode d'exercice de la Direction générale dissociant les fonctions de Président du Conseil d'administration et de Directeur général à même d'éviter les problèmes de concentration au sein d'une même personne des conflits d'intérêts entre exécution et supervision, est accueillie favorablement par Proxinvest. Ainsi, nous recommandons l'approbation de la nomination de David Horn Solomon (résolution 1). Cependant, nous recommandons l'o...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.